The autosomal recessive syndrome ataxia-telangiectasia (A-T) is of public health importance because there is evidence that A-T heterozygotes, estimated to comprise 1.4% of the United States white population, are predisposed to cancer, particularly female breast cancer with onset before age 65. The initial mapping of the principal, perhaps only, A-T gene to 11q22-23 provides the basis for full characterization of this gene at the DNA and protein level, detection of A-T heterozygotes in A-T families and the general population, strong confirmation of the association of A-T heterozygosity with specific cancers, understanding of the gene-environment interactions that produce these cancers, and, in the long term, prevention of these cancers in all A-T heterozygotes in the general population. Fine mapping with available and to-be-developed highly polymorphic DNA probes will be done to localize the A-T locus at 11q22-23 and to resolve the question of non-allelic heterogeneity. Assay systems will be developed to test candidate regions for the A-T locus and available cosmid clones will be tested to see if they transform A-T homozygous cells to the heterozygous phenotype. Ultimately, the specific region that appears to contain the A-T allele will be confirmed in these systems, and the A-T allele characterized. A case-control analysis based on direct identification of A-T heterozygotes will test the hypothesis that A-T heterozygotes are predisposed to breast and other cancers. Allele-specific or closely linked DNA probes will be used to determine which blood relatives with cancer are A-T heterozygotes, so that a newly developed, well controlled, statistically powerful method can be used to provide strong independent evidence about specific cancers associated with A-T heterozygosity. Breast cancer is the highest priority.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA050489-06
Application #
2093806
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Project Start
1990-04-01
Project End
1996-02-29
Budget Start
1994-03-01
Budget End
1996-02-29
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
New York Medical College
Department
Pediatrics
Type
Schools of Medicine
DUNS #
City
Valhalla
State
NY
Country
United States
Zip Code
10595
Athma, P; Rappaport, R; Swift, M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92:130-4
Athma, P; Fidahusein, N; Swift, M (1995) Single base polymorphism linked to the ataxia-telangiectasia locus is detected by mismatch PCR. Biochem Biophys Res Commun 210:982-6
Athma, P; Liu, J; Swift, M (1995) PCR detection of the Taq1 restriction fragment length polymorphism linked to the ataxia telangiectasia locus. Clin Chem 41:625-6
Lench, N J; Athma, P; Ottaiano, A et al. (1994) DNA marker D11S384 shows zero recombination with the ataxia-telangiectasia locus in North American families. Int J Radiat Biol 66:S67-9
Swift, M; Heim, R A; Lench, N J (1993) Genetic aspects of ataxia telangiectasia. Adv Neurol 61:115-25
Lench, N J; Carpenter, S; Swift, M et al. (1991) AvaII RFLP detected by the anonymous DNA segment p10E5.SC1 [D11S806] on chromosome 11q22-23. Nucleic Acids Res 19:5796